COST-EFFECTIVENESS OF FINERENONE FOR CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES IN KOREA: RESULTS OF THE FINE-CKD MODEL
Author(s)
Han-Sang Baek1, Dae Jung Kim2, Kyoung Hwa Ha, PhD3.
1pf, Catholic University of Korea, Seoul, Korea, Republic of, 2Korea, Republic of, 3Yonsei University College of Medicine, Seoul, Korea, Republic of.
1pf, Catholic University of Korea, Seoul, Korea, Republic of, 2Korea, Republic of, 3Yonsei University College of Medicine, Seoul, Korea, Republic of.
OBJECTIVES: Chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) is associated with substantial morbidity, mortality, and healthcare costs. Despite the renal and cardiovascular benefits of finerenone, its economic value in the South Korean healthcare setting remains unclear.
METHODS: Using a validated Markov model based on the FINE-CKD framework, we conducted a cost-utility analysis from the perspective of the South Korean healthcare system. Clinical inputs were derived from the FIDELIO-DKD trial, and cost inputs were obtained from recent Health Insurance Review and Assessment Service data. The outcomes included quality-adjusted life-years (QALYs), life-years (LYs), and incremental cost-utility ratios (ICURs). Deterministic and probabilistic sensitivity analyses were performed.
RESULTS: Over a lifetime horizon, finerenone plus standard of care (SoC), compared with SoC alone, yielded an additional 0.1151 QALYs and 0.1601 LYs per patient. The total costs increased by $1,295.75, primarily because of higher medication costs; however, this increase was partly offset by lower CKD-related and cardiovascular event costs. The ICUR was $11,262 per QALY gained, which was below the commonly accepted willingness-to-pay threshold. In the probabilistic sensitivity analysis, finerenone was cost-effective in 50.1% and 54.8% of the simulations at willingness-to-pay thresholds of USD 15,385 and USD 23,007 per QALY, respectively. Cost-effectiveness was driven primarily by delayed progression to advanced CKD, particularly stage 5, which requires renal replacement therapy.
CONCLUSIONS: Finerenone potentially constitutes a cost-effective treatment option for patients with CKD and T2DM in South Korea
METHODS: Using a validated Markov model based on the FINE-CKD framework, we conducted a cost-utility analysis from the perspective of the South Korean healthcare system. Clinical inputs were derived from the FIDELIO-DKD trial, and cost inputs were obtained from recent Health Insurance Review and Assessment Service data. The outcomes included quality-adjusted life-years (QALYs), life-years (LYs), and incremental cost-utility ratios (ICURs). Deterministic and probabilistic sensitivity analyses were performed.
RESULTS: Over a lifetime horizon, finerenone plus standard of care (SoC), compared with SoC alone, yielded an additional 0.1151 QALYs and 0.1601 LYs per patient. The total costs increased by $1,295.75, primarily because of higher medication costs; however, this increase was partly offset by lower CKD-related and cardiovascular event costs. The ICUR was $11,262 per QALY gained, which was below the commonly accepted willingness-to-pay threshold. In the probabilistic sensitivity analysis, finerenone was cost-effective in 50.1% and 54.8% of the simulations at willingness-to-pay thresholds of USD 15,385 and USD 23,007 per QALY, respectively. Cost-effectiveness was driven primarily by delayed progression to advanced CKD, particularly stage 5, which requires renal replacement therapy.
CONCLUSIONS: Finerenone potentially constitutes a cost-effective treatment option for patients with CKD and T2DM in South Korea
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE18
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory), Diabetes/Endocrine/Metabolic Disorders (including obesity), Urinary/Kidney Disorders